Carrier Cells for Delivery of Oncolytic Measles Virus into Tumors: Determinants of Efficient Loading
- 109 Downloads
Oncolytic measles virus (OMV) is a promising antitumor agent. However, the presence of anti-measles neutralizing antibodies (NAbs) against the hemagglutinin (H) protein of OMV is a major barrier to the therapeutic application of OMV in clinical practice. In order to overcome this challenge, specific types of cells have been used as carriers for OMV. Differential loading strategies appear to result in different therapeutic outcomes; despite this, only few studies have reported practical ex vivo loading strategies required for effective treatment. To this end, we systematically evaluated the antitumor efficacy of OMV using different loading strategies; this involved varying the in vitro loading duration and loading dose of OMV. We found that improved oncolysis of carrier cells was achieved by a prolonged loading duration in the absence of NAbs. However, the enhanced oncolytic effect was abrogated in the presence of NAbs. Further, we found that the expression of H protein on the surface of carrier cells was predominantly determined by the loading duration rather than the loading dose. Finally, we showed that NAbs blocked viral transfer by targeting H protein prior to the occurrence of cell-to-cell interactions. Our results provide comprehensive information on the determinants of an effective loading strategy for carrier cell-based virotherapy; these results may be useful for guiding the application of OMV as an antitumor agent in clinical practice.
KeywordsOncolytic measles virus (OMV) Cell carriers Loading strategy Tumor
The authors thank Prof. Dr. Stephen J. Russell for providing modified oncolytic MV strains. This study was supported in part by the National Natural Science Foundation of China (81472820, 81773255, 81071860 and 81602702), Jiangsu Special Program for Clinical Medical Science and Technology (BL2014054), the Natural Science Foundation of Jiangsu Province of China (BK20160126), and the Fundamental Research Funds for the Central Universities (021414380223 and 14380336/1-2). Six talent peaks project in Jiangsu Province to JW.
JW designed the study; CX, MX, GM and CL performed the experiments; CX and MX analyzed the data. CX and JW wrote the manuscript. JW and AJ finalized the manuscript.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
Animal and Human Rights Statement
The protocol of this study was approved by the Research Ethics Committee of the Medical School of Nanjing University. The experiments were carried out in accordance with approved guidelines and regulations. All participants were provided with written informed consent.
- Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ (2010) Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 70:875–882CrossRefPubMedPubMedCentralGoogle Scholar
- Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E, Russell SJ, Dietz AB, Peng KW (2009) Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res 15:7246–7255CrossRefPubMedPubMedCentralGoogle Scholar
- Peng KW, Dogan A, Vrana J, Liu C, Ong HT, Kumar S, Dispenzieri A, Dietz AB, Russell SJ (2009) Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am J Hematol 84:401–407CrossRefPubMedPubMedCentralGoogle Scholar